Skip to main content
SpringerLink
Log in

Everolimus vs MMF: risks of pericardial effusion vs CAV

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Starling R, Pauly D, Wang S, Cantin B, Ross H, Burton J, Eisen HJ, Keogh A, Dong G, Jiang H, Cines M, Lopez P, Kobashigawa J.De Novo Heart Transplant Recipients at Increased Risk of Cardiac Allograft Vasculopathy: IVUS Analysis of Specific Subpopulations Treated with Everolimus Versus MMF. American Transplant Congress -- 11th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation: abstr. 336, 30 Apr 2011. Available from: URL: http://2011.atcmeeting.org

  2. Zuckermann A, Eisen H, Kobashigawa J, Ross H, Wang S, Lehmkuhl H, Rinaldi M, Torre G, Yonan N, Arizon J, Pellegrini C, Lopez P, Dong G, Panis C, Hirt S.Wound Healing Events and Effusions with Everolimus Versus MMF Based Regimens in De Novo Heart Transplant Recipients. 31st Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation: abstr. 245, 13 Apr 2011. Available from: URL: http://www.ishlt.org

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Everolimus vs MMF: risks of pericardial effusion vs CAV. React. Wkly. 1354, 4 (2011). https://doi.org/10.2165/00128415-201113540-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201113540-00008

Keywords

Search

Navigation